0550 GMT - Wuxi Biologics' near-to-medium term growth trajectory looks stable, CGS International analyst Lily Wang says in a note. The company has a resilient order backlog, which showed growth in 2024, signaling minimal disruption from U.S. geopolitical concerns, Wang says. CGSI raises its revenue forecasts by 7.2% and 10.6% for 2025 and 2026, respectively. It also lifts the target price to HK$25.06 from HK$10.87, to reflect more optimism around manufacturing projects. However, CGSI keeps a hold rating due to tariff uncertainty, as potentially higher costs from overseas facilities could pressure its gross profit margin. Clients may shift to rival manufacturers who are expanding their U.S. production capacity, adding risks to Wuxi Biologics' market share, Wang adds. Shares are 1.1% higher at HK$22.95. (kimberley.kao@wsj.com)
(END) Dow Jones Newswires
April 24, 2025 01:50 ET (05:50 GMT)
Copyright (c) 2025 Dow Jones & Company, Inc.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。